Top Page
Acrux
(Sydney:ACR)
Acrux (ACR) vs. S&P 500 (SPY)
Acrux Business Overview & Revenue Model
Acrux Financial Statement Overview
| Breakdown | ||||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 5.09M | 8.43M | 1.72M | 1.34M | 1.25M | Gross Profit |
| 1.13M | 1.95M | -4.65M | -7.59M | -3.76M | EBIT |
| -8.57M | -3.39M | -12.97M | -16.25M | -12.08M | EBITDA |
| -8.06M | -2.79M | -12.29M | -15.59M | -11.37M | Net Income Common Stockholders |
| -5.80M | -764.00K | -9.83M | -12.63M | -9.47M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 2.94M | 6.23M | 5.83M | 15.27M | 9.21M | Total Assets |
| 8.96M | 14.30M | 15.27M | 24.20M | 18.52M | Total Debt |
| 3.70M | 2.35M | 2.08M | 2.23M | 2.40M | Net Debt |
| 759.00K | -3.88M | -3.75M | -13.04M | -6.80M | Total Liabilities |
| 5.69M | 5.60M | 6.18M | 5.73M | 5.67M | Stockholders Equity |
| 3.28M | 8.70M | 9.09M | 18.47M | 12.85M |
| Cash Flow | Free Cash Flow | |||
| -4.58M | 584.00K | -9.28M | -11.52M | -8.79M | Operating Cash Flow |
| -4.30M | 703.00K | -8.82M | -11.41M | -8.53M | Investing Cash Flow |
| -276.00K | -119.00K | -465.00K | -102.00K | -254.00K | Financing Cash Flow |
| 1.29M | -183.00K | -155.00K | 17.58M | -159.00K |
Acrux Technical Analysis
Acrux Peers Comparison
Acrux Corporate Events
Acrux Limited has announced the appointment of John Warmbrunn as the new CEO and Managing Director, effective June 1, 2025, following the retirement of Michael Kotsanis. Warmbrunn brings over 25 years of experience in the healthcare sector, with a strong track record in international business growth and leadership roles at companies like Ego Pharmaceuticals and Bendigo Community Telco. His appointment is expected to drive Acrux’s next phase of growth, particularly in expanding its international market presence.
Acrux Limited has reported significant growth in product-based revenue following the successful launch of new products in late 2024 and early 2025. The company raised $3.989 million through a placement and share purchase plan, and secured $1.729 million in short-term funding from Radium Capital. These financial activities, coupled with the positive market reception of their products, position Acrux to achieve its strategic goal of sustaining future product development.
Acrux Limited announced a change in the address of its registry office in Sydney, effective from April 14, 2025. The registry, managed by MUFG Corporate Markets (AU) Limited, will relocate to Liberty Place, Level 41, 161 Castlereagh St, Sydney. This change is part of the company’s ongoing operational adjustments and does not affect contact details, ensuring continuity for stakeholders.
Acrux Limited announced a change in the director’s interest, with Ross Dobinson acquiring 571,428 free attaching options. This change reflects the issue of options approved at an Extraordinary General Meeting in February 2025, aligning with the terms for Placement and SPP participants. The announcement indicates a strategic move to incentivize leadership and align interests with stakeholders, potentially impacting the company’s operational dynamics and stakeholder relations.
Acrux Limited has announced the quotation of 8,829,411 options on the Australian Securities Exchange (ASX), set to expire on February 19, 2027. This move is part of previously announced transactions and could enhance the company’s financial flexibility and market presence, potentially impacting stakeholders by increasing investment opportunities.
Acrux Limited has received a $1.73 million advance from Radium Capital related to its FY25 R&D Tax Incentive. This funding provides early access to the expected rebate, supporting product development and working capital management, and is secured against the anticipated rebate from the Australian Taxation Office.
Acrux Limited has announced the issuance of 571,428 fully paid ordinary shares to its directors, following approval at an Extraordinary General Meeting. These shares are part of a larger Share Placement and Share Purchase Plan, and were issued without disclosure to investors under specific sections of the Corporations Act. This move reflects the company’s ongoing strategic efforts to strengthen its financial positioning and engage stakeholders in its growth initiatives.
Acrux Limited has announced the quotation of 571,428 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of March 3, 2025. This move is part of a previously announced transaction, potentially enhancing the company’s market presence and providing additional liquidity for stakeholders.
Acrux Limited has released an investor presentation highlighting its focus on the development and commercialization of topical pharmaceuticals. The presentation includes forward-looking statements about the company’s future performance, emphasizing the uncertainties and risks involved. These statements are based on current economic conditions and assumptions about future events, but actual results may vary due to factors like resource availability, regulatory actions, and competition.
Acrux Limited announced an upcoming Investor Webinar where management will present the company’s half-year results for the period ending December 31, 2024. This event provides an opportunity for stakeholders to engage directly with the management team, as questions submitted in advance will be addressed following the presentation. The webinar reflects Acrux’s commitment to transparency and stakeholder engagement, potentially impacting its market positioning and investor relations.
Acrux Limited reported a significant decline in revenues from ordinary activities, down 70% to $1.71 million for the half-year ended December 31, 2024. The company also experienced a 6% increase in net loss, totaling $3.425 million, with no dividends declared or paid during this period. This financial downturn reflects challenges in Acrux’s market positioning and could have implications for its stakeholders, as the net tangible asset per ordinary security also decreased from $0.02 to $0.01.
Acrux Limited has released information regarding the top 20 option holders and distribution schedule for its new class of quoted securities, following its Appendix 2A Application for Quotation of Securities. This announcement outlines the terms and conditions as per the Options Prospectus dated 17 January 2025. The release signifies Acrux’s ongoing efforts to enhance its financial operations and market presence, which may impact its industry positioning and offer potential opportunities for stakeholders.
Acrux Limited has announced a change in the director’s interest notice, specifically regarding the interest of Director Tim Oldham. The change includes the acquisition of 285,714 free attaching options with no securities disposed of, which were approved for issue at the Extraordinary General Meeting held on February 3, 2025. This development may influence the company’s operational strategies and could have implications for stakeholders due to the expanded securities holdings of a key director.
Acrux Limited has announced a change in its director’s interests, with Michael Kotsanis acquiring 857,142 free attaching options. This issuance of options, approved at the recent Extraordinary General Meeting, reflects the company’s ongoing efforts to align management incentives with shareholder interests and may influence the company’s strategic direction.
Acrux Limited announced a change in Director Geoffrey Brooke’s interests involving the issuance of 285,714 free attaching options. This issuance was part of a board-approved plan and aligns with other Placement and SPP participants, potentially enhancing the director’s stake and signaling confidence in the company’s future prospects.
Acrux Limited has disclosed a change in its director’s interest notice. Director Don Brumley has acquired 2,285,714 free attaching options, which were approved for issuance at an Extraordinary General Meeting on February 3, 2025. This change reflects Acrux’s ongoing efforts to align its executive interests with corporate strategies, potentially impacting stakeholder perceptions positively.
Acrux Limited has announced the issuance of options in accordance with its Options Prospectus dated January 17, 2024, which was approved at an Extraordinary General Meeting on February 3, 2025. This development includes the application for quotation of 151,642,766 new securities, which will be issued on February 19, 2025. The issuance aims to enhance Acrux’s financial flexibility and market presence.
Acrux Limited announced an extension of the closing date for its offer of free Attaching Options to subscribers of its Share Placement and Share Purchase Plan. Originally set to close on 17 February 2025, the deadline has been extended to 31 March 2025, allowing subscribers more time to accept the offer. This decision could enhance stakeholder engagement and potentially increase participation in the offer, which aligns with Acrux’s strategic focus on expanding its market presence.
Acrux Limited announced the issuance of 1,609,200 performance rights as part of its employee incentive scheme, which are unquoted on the ASX. This move reflects the company’s strategy to retain talent and align employee incentives with company performance, potentially impacting its operations through enhanced employee motivation and engagement.
Acrux Limited announced the issuance of 780,275 fully paid ordinary shares to be quoted on the ASX. This issuance, part of an employee incentive scheme, reflects the company’s ongoing efforts to align employee interests with corporate goals and could enhance its market presence by potentially improving stakeholder engagement.
Acrux Limited has announced the issuance of 3,714,284 fully paid ordinary shares to its directors, following shareholder approval at an Extraordinary General Meeting earlier in February. These Director Placement Shares were issued under the same terms and conditions as previous shares from the Share Placement and Share Purchase Plan announced in December 2024. The company has complied with the relevant provisions of the Corporations Act and confirms that there is no excluded information related to this issuance.
Acrux Limited has announced the quotation of 3,714,284 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of February 13, 2025. This development marks a strategic move for Acrux, potentially enhancing its market presence and liquidity, and offering stakeholders new opportunities for growth within the pharmaceutical sector.
Acrux Limited has announced the issuance of 3,714,284 fully paid ordinary shares to Directors as part of a previously approved Share Placement and Share Purchase Plan. This move aligns with the company’s efforts to strengthen its financial position and support its operations in the specialty pharmaceutical industry, with no excluded information required to be disclosed under the Corporations Act.
Acrux Limited announced a change in the interests of their director, Geoffrey Brooke, regarding company securities. Dr. Brooke acquired 285,714 ordinary shares through a Share Placement approved at an EGM, under the same terms as other participants, reflecting continued confidence in the company’s strategic initiatives.